Related Experiment Video

Updated: Aug 23, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

The role of proteasome inhibitors in solid tumors

David J Park1, Heinz-Josef Lenz

  • 1Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, USA.

Annals of Medicine
|July 1, 2004
PubMed

Insights

The proteasome protein degradation pathway is a novel cancer treatment target. Bortezomib (Velcade), a proteasome inhibitor, shows anti-cancer activity and is well-tolerated in clinical trials.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • The proteasome is a cellular complex responsible for protein degradation.
  • Proteasome substrates are crucial in cell cycle regulation, tumor suppression, apoptosis, transcription, and angiogenesis.
  • Inhibiting the proteasome presents a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To evaluate bortezomib (Velcade) as a novel proteasome inhibitor for cancer therapy.
  • To assess the anti-cancer activity and tolerability of bortezomib in preclinical and clinical settings.

Main Methods:

  • Preclinical studies evaluating bortezomib's efficacy.
  • Early-phase clinical trials in patients with solid tumors and hematological malignancies.
  • Combination therapy studies with traditional chemotherapeutic drugs.

Main Results:

  • Bortezomib demonstrated anti-cancer activity in both solid tumors and hematological malignancies.
  • The drug was found to be relatively well-tolerated in clinical trials.
  • Bortezomib showed efficacy as a single agent and in combination therapy.

Conclusions:

  • Proteasome inhibition, exemplified by bortezomib, is a viable therapeutic approach for cancer.
  • Bortezomib is an active and well-tolerated agent for treating various cancers.
  • Ongoing clinical trials are further investigating bortezomib's role in solid tumor treatment.

More Related Videos

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...